Insulet Stock

Insulet EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Insulet (PODD) as of Aug 1, 2026 is 33.97. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 52.10 — a change of -34.80% (lower).

EV/EBIT

33.97

YoY

-34.80%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Insulet is 2026 33.97 . EV/EBIT (Enterprise Value to EBIT) of Insulet was 2025 52.10 . It decreases by -34.80% lower compared to the previous year.

The Insulet EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
218.75 base
Jan 1, 2020
307.62 base
Jan 1, 2021
227.36 base
Jan 1, 2022
0.00 base
Jan 1, 2023
68.90 base
Jan 1, 2024
62.61 base
Jan 1, 2025
42.39 base
Jan 1, 2026 (e)
31.14 base
YEARPRICE-TO-EBIT
2026 est 31.14
2025 42.39
2024 62.61
2023 68.90
2022 -
2021 227.36
2020 307.62
2019 218.75
2018 176.66
2017 -543.97
2016 -174.11
2015 -44.17
2014 -210.38
2013 -69.62
2012 -28.45
2011 -21.03
2010 -18.29
2009 -9.11
2008 -2.40
2007 -11.95
2006 -
Access this data via the Eulerpool API

Insulet Valuation

Details

Historical Valuation Multiples

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Insulet's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Insulet's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Insulet's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Insulet grows earnings faster than its peers.

Insulet Stock analysis

What does Insulet do? Insulet Corp is an American company that was founded in 2000 and is headquartered in Acton, Massachusetts. Its goal is to improve the quality of life for people with diabetes by developing innovative products that make living with this chronic disease easier. Insulet Corp is known for its product "OmniPod." The OmniPod is a wireless, portable disposable insulin pump system that offers an alternative option to traditional pumping and insulin delivery systems. The OmniPod system consists of two small devices: a pod worn on the skin and a PDM (Personal Diabetes Manager) that regulates insulin delivery. The pod contains an insulin reservoir that communicates wirelessly with the PDM. The insulin dose is administered directly into the body without needles or tubes. Insulet Corp is also introducing the "OmniPod DASH System." This new system combines the proven design of the OmniPod pod with a new color touchscreen handheld device that allows for even easier operation. The DASH system also offers the ability to control insulin dosing from a smartphone, which can be taken with diabetics wherever they go. The success of the OmniPod system has made Insulet Corp a leading company in the diabetes industry. The company has also developed and introduced products and services in other areas of diabetes treatment. Insulet Corp has developed another product called "Amigo." This product is a personalized travel and training program for people who require insulin. Amigo offers specialized and personalized training to support diabetics in managing complex situations. It also offers diet and exercise plans to make living with diabetes easier. Insulet Corp has also developed a software called "OmniPod Horizon." This software is a closed-loop system that automatically adjusts insulin dosing to keep blood sugar levels within the target range. The system is currently in the development phase and is expected to be released in 2020. Insulet Corp has also developed a program called the "OmniPod Partner Program," which targets doctors and pharmacists. The program provides training and educational materials for healthcare providers to help them better treat and manage their patients. Since 2009, Insulet Corp has been listed on the NASDAQ stock exchange and has continuously evolved since then. The company currently has over 1500 employees and operates in North America, Europe, and the Middle East. Insulet Corp is a company focused on the development of innovative, life-changing products and services. It is expected to continue to play a significant role in improving the quality of life for people with diabetes in the future. Insulet is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Insulet stock

EV/EBIT (Enterprise Value to EBIT) of Insulet is 33.97 in 2026.

Access this data via the Eulerpool API

Valuation — Insulet

All Key Metrics — Insulet